Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes.
Phase of Trial: Phase I
Latest Information Update: 03 Dec 2010
At a glance
- Drugs Glucagon-like peptide-1 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 03 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Sep 2010 New trial record